AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06346145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Type of surgery assigned by surgeon in consultation with patient
Study NCT06346145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care can consist of dietary intervention, physiotherapy or drug treatment in accordance to the care given in the region of Sweden where the patient resides.
Study NCT04674228 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT01211951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809
Study NCT01211951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04286295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
Study NCT04286295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
Study NCT04286295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Lozenge Product
Description: Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
Study NCT04380233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome
Description: The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
Study NCT05436418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant
Study NCT04380233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Study NCT05562648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy techniques
Description: Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors.
Study NCT05562648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrophysical agents
Description: TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord.
Study NCT05065619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-2766 High dose (3.75 µg)
Description: Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Study NCT05065619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Study NCT05065619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-2766 Low dose
Description: Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Study NCT05590676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg.
Study NCT05436418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
Study NCT04892303 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)
Description: To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
Study NCT04914312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maqui berry/omeg-3 fatty acids
Description: 2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
Study NCT04914312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
Study NCT05505786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wide stance width
Description: Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
Study NCT06229093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma
Description: For the OAg group, the visual component of multimodal stimulation will have the same properties as for the other group, except it will also be additionally amplitude-modulated in the gamma-band (30-60 Hz) range, resulting in a detectable flicker over-and-above the beat-level modulation.
Study NCT06229093 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Synchrony
Description: For the OA group, the lights will be tuned to delta-band frequencies (1-4 Hz) in the music, which corresponds to the beat-level frequency in most music. Thus, the lights automatically adapt to the rhythm of the music, pulsing on the beat and changing color on strong beats.
Study NCT05506345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creative Drama Workshop
Description: * The host introduces the theme and stressor scene of this workshop~  * Nursing students group discussion~    * Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events
Study NCT06226870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal tretment
Description: traditional therapy
Study NCT05436418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is > 1000 cells/mm3 for three days or > 5000 for one day.
Study NCT06226870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biodentin VPT
Description: Alternative therapy
Study NCT06226870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Alternative therapy
Study NCT04826250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timing of medication
Description: Either morning or nighttime medication
Study NCT06252662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: block duration extension additive
Study NCT06252662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Control arm, comparison for block duration with dexmedetomidine
Study NCT04728620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Care Gaps Patient Portal Intervention
Description: The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
Study NCT05414929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Description: HPV self-sampling (Cobas Uniswab)
Study NCT05029726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine
Description: Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
Study NCT05029726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline in 30cc syringes administered using ESPB technique
Study NCT06090708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yogurt with probiotic bacteria
Description: Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
Study NCT05841693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
Study NCT05841693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will be offered same amount of placebo fluid.
Study NCT05696327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tyler Twist Exercises
Description: Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
Study NCT05696327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
Study NCT06000111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 Days of face-down positioning
Description: Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
Study NCT06000111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 Days of face-down positioning
Description: Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
Study NCT06232590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (comfilcon A)
Description: Multifocal monthly replacement contact lens for 1 month
Study NCT06232590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (lehfilcon A)
Description: Multifocal monthly replacement contact lens for 1 month
Study NCT05543551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing with Resistance Training
Description: Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees.
Study NCT05590234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
Study NCT05590234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 20 ml of bupivacaine 0.25%,
Study NCT05590234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20 ml of normal saline 0.9%.
Study NCT06390982 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
Study NCT05543551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic breathing with out resistance training
Description: Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed
Study NCT05425355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) acetaminophen + oral placebo
Description: Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
Study NCT05425355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) placebo plus oral acetaminophen
Description: Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
Study NCT05442190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Study NCT05442190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
Study NCT05578872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion
Study NCT05578872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion
Study NCT05578872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab administered by intravenous (IV) infusion
Study NCT05578872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Ipilimumab administered by intravenous (IV) infusion
Study NCT05649137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study NCT06390982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV on Day 1 of each 21-day cycle.
Study NCT06390982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
Study NCT05649137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study NCT04535375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Doppler Ultrasound of venous cerebral circulation
Description: No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
Study NCT05649137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study NCT06551987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: 6 weekly, 50-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
Study NCT06551987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Therapy for Insomnia
Description: 4 weekly, 30-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
Study NCT06294535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reconstruction of orbital walls
Description: under GA, incision to access to orbital walls. Then insertion of prebent titanium mesh or customized titanium implant and fixation with miniscrews, examination of ocular motility using forced duction test followed by closure of flap.
Study NCT05384275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Therapy
Description: High Flow Nasal Oxygen (Airvo2 Device)
Study NCT04850313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProProKera Plus®
Description: ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
Study NCT06227455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary alveolar ridge augmentation
Description: The surgical procedure involves careful flap reflection, autogenous graft harvesting, and placement and fixation of the barriers over mixture of Autogenous graft and xenograft particles.